Actively Recruiting

Phase 1
All Genders
NCT05147701

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

Led by The Foundation for Orthopaedics and Regenerative Medicine · Updated on 2025-04-17

20

Participants Needed

2

Research Sites

204 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This trial will study the safety and efficacy of intravenous and sub-tenon delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of non-arteritic ischemic optic neuropathy

CONDITIONS

Official Title

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of NAION (non-arteritic ischemic optic neuropathy)
  • Understanding and willingness to sign a written informed consent document
Not Eligible

You will not qualify if you...

  • Active infection
  • Active cancer
  • Chronic multisystem organ failure
  • Pregnancy
  • Clinically significant abnormalities on pre-treatment laboratory evaluation
  • Medical condition that could compromise patient's safety
  • Continued drug abuse
  • Pre-menopausal women not using contraception
  • Previous organ transplant
  • Hypersensitivity to sulfur

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Medical Surgical Associates Center

St John's, Antigua and Barbuda

Actively Recruiting

2

Center for Investigation in Tissue Engineering and Cellular Therapy

Buenos Aires, Argentina

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here